FIELD: biochemistry.
SUBSTANCE: invention relates to an anti-PD-1 antibody which specifically binds to PD-1 (protein 1 of programmable cell death). Also disclosed is a nucleic acid encoding said antibody; an expression vector, a cell line and a host cell producing said antibody; pharmaceutical composition containing said antibody. Disclosed is a method of producing said antibody; method of treating and a method for increasing immunogenicity or activity of an immune cell using said antibody.
EFFECT: invention is capable to effectively treat diseases associated with PD-1.
45 cl, 5 ex, 4 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
